Press Detail

PRESS RELEASE

Biotest Supervisory Board appoints new Management Board member

- Dr Jörg Schüttrumpf appointed to the Board as Chief Scientific Officer (CSO)

- Development of trimodulin and Fibrinogen to be accelerated

- Additional phase III trial with Covid-19 patients

Dreieich, 9 December 2021. At its meeting today, the Supervisory Board of Biotest AG appointed Dr Jörg Schüttrumpf (47) as a further member of the company's Management Board with effect from 1 January 2022.

As 'Chief Scientific Officer', Dr Schüttrumpf will be responsible within the Biotest Group for the area of research and development, including drug safety and drug approval. Dr Schüttrumpf has been responsible for global research at Biotest AG since 2012 and for research and development since 2015.

This personnel decision is directly accompanied by the Supervisory Board's approval of an expanded budget for the accelerated development of trimodulin in sCAP and of Fibrinogen also for the USA. In addition, the Supervisory Board approved the start of an additional phase III trial with trimodulin in Covid-19 patients, which had not previously been planned. As announced on 23 November 2021, this development will be funded by the German Federal Ministry of Education and Research (BMBF) and the German Federal Ministry of Health (BMG). Biotest will have to bear 20% of the funds required for this study itself.

"We are happy that Dr Schüttrumpf will be joining the Board of Biotest AG in the future. He has been very successful in developing research and development at Biotest and is a management personality with an impressive professional vitae. His appointment strengthens the company's strategic focus on growth as a provider of innovative plasma therapeutics," emphasises Rolf Hoffmann, Chairman of the Supervisory Board of Biotest AG.

About Biotest
Biotest is a provider of plasma proteins and biological drugs. With a value added chain that extends from pre-clinical and clinical development to worldwide sales, Biotest has specialised primarily in the areas of clinical immunology, haematology and intensive care medicine. Biotest develops and markets immunoglobulins, coagulation factors and albumin based on human blood plasma. These are used for diseases of the immune and haematopoietic systems. Biotest has more than 1,900 employees worldwide. The ordinary and preference shares of Biotest AG are listed in the Prime Standard on the German stock exchange.

IR contact
Dr Monika Buttkereit
Phone: +49-6103-801-4406
Mail: investor_relations@biotest.de

PR contact
Dirk Neumüller
Phone: +49-6103-801-269
Mail: pr@biotest.com

Biotest AG, Landsteinerstr. 5, 63303 Dreieich, Germany, www.biotest.com

Ordinary shares: securities' ID No. 522720; ISIN DE0005227201
Preference shares: securities' ID No. 522723; ISIN DE0005227235
Listing: Frankfurt (Prime Standard)
Open Market: Berlin, Düsseldorf, Hamburg/ Hanover, Munich, Stuttgart, Tradegate

Disclaimer
This document contains forward-looking statements on overall economic development as well as on the business, earnings, financial and assets position of Biotest AG and its subsidiaries. These statements are based on current plans, estimates, forecasts and expectations of the company and are thus subject to risks and elements of uncertainty that could result in significant deviation of actual developments from expected developments. The forward-looking statements are only valid at the time of publication. Biotest does not intend to update the forward-looking statements and assumes no obligation to do so.